What is the difference between TAM, SAM, and SOM for a medical device?

TAM (Total Addressable Market) is the full theoretical market: every patient or procedure that could benefit from the device, at the expected ASP. SAM (Serviceable Addressable Market) is the portion of TAM reachable with your specific regulatory clearance, geographic reach, and commercial infrastructure. SOM (Serviceable Obtainable Market) is the realistic share of SAM you can capture in a defined period given your sales capacity and competitive dynamics.

Where can I find procedure volume data for medical device market sizing?

The most commonly used publicly available sources are: the CDC's National Center for Health Statistics (https://www.cdc.gov/nchs/index.htm) for hospital discharge and ambulatory surgery data; AHRQ's Healthcare Cost and Utilization Project (https://www.hcup-us.ahrq.gov/) for inpatient and outpatient procedure data; CMS's Medicare claims data (https://www.cms.gov/data-research/statistics-trends-and-reports/medicare-fee-service-provider-utilization-payment-data) for procedure volumes by CPT code in the Medicare population; and the FDA's MAUDE database and 510(k) database for market information from existing cleared device submissions.

Do I need to buy a market research report for my TAM analysis?

Not necessarily, though proprietary reports from firms like GlobalData, Evaluate MedTech, or IQVIA provide segmentation and competitive share data that is difficult to replicate from public sources. For early-stage market sizing, building a bottom-up model from public epidemiological and procedure data is often more defensible than citing a single market research figure. Proprietary reports are most valuable for competitive share data and for validating public-source estimates.

How do medtech investors evaluate market sizing?

Experienced medtech investors evaluate the methodology, not just the number. A $500M SAM with transparent methodology, conservative adoption assumptions grounded in analogous launches, and explicit regulatory clearance boundaries is more credible than a $5B TAM with no visible derivation. Investors also evaluate whether the founding team understands the reimbursement environment and can explain how hospital procurement decisions are made for devices in the category.

How does regulatory clearance affect my market size calculation?

The cleared intended use in your 510(k) or approved indications in your PMA defines the patient population and procedures you can legally market the device to address. If your cleared indication covers a specific subset of a larger patient population, the SAM is that subset, not the full population. Expanding the SAM requires a new or supplemental submission broadening the intended use.

What is a realistic market share assumption for a new medical device?

It depends on the category and competitive dynamics. New devices entering categories with well-established competitors and hospital purchasing contracts typically achieve 5 to 15% SAM penetration in the first three to five years of commercial launch. New devices creating a new category (no direct competition) can achieve higher initial penetration but often face slower adoption due to longer clinician learning curves and more complex hospital budget approval processes. Using published analogous launch data as a calibration is more defensible than selecting a percentage without comparative support.

Should my market sizing include international markets from the start?

Only if international commercial launch is part of the planning period covered by the analysis. International markets require separate regulatory authorizations (CE marking under the MDR in the EU, PMDA approval in Japan, NMPA approval in China, etc.) and separate commercial infrastructure. Including international markets in the SAM without accounting for those regulatory and commercial timelines produces an overstatement of the reachable near-term market. It is common to show a US-only near-term SAM and a global long-term TAM, with the distinction clearly labeled.

How to Size the Total Addressable Market for a Medical Device: TAM, SAM, and SOM in Medtech

Direct answer: TAM (Total Addressable Market) for a medical device is the total annual revenue opportunity if every patient or procedure that could benefit from the device received it. SAM (Serviceable Addressable Market) narrows that to the segment reachable with your current regulatory clearance, clinical indication, and commercial infrastructure. SOM (Serviceable Obtainable Market) is the realistic share you can capture in a defined time period given competitive dynamics, sales capacity, and adoption rates. Medical device market sizing uses two primary methods: top-down (starting from published market data or epidemiology) and bottom-up (building from procedure or patient volumes multiplied by device price). Both have significant limitations; the most credible analyses use both methods and triangulate between them. (As of July 2026.)

Every medtech pitch deck has a market size slide. Most of them are wrong in ways that experienced investors recognize immediately: a "$25 billion orthopedic market" TAM for a device that addresses one surgical sub-procedure, or a SOM built on a best-case adoption curve with no comparison to analogous device launches.

Market sizing in medtech is genuinely difficult. The data is fragmented across epidemiological databases, claims data, and proprietary market research reports. Regulatory clearance boundaries constrain the addressable market in ways that do not apply to consumer products. Reimbursement structures affect what "revenue" actually means. And medtech adoption curves are typically slower than SaaS or consumer adoption, which means that even correct market sizing produces over-optimistic SOM estimates if the adoption timeline is wrong.

This article explains how to build a defensible TAM, SAM, and SOM for a medical device, what data sources to use, and what the most common mistakes look like.

Why Market Sizing Matters Beyond the Pitch Deck

Market sizing is not primarily an investor communication exercise. A well-constructed market analysis drives commercial decisions throughout the device lifecycle:

Go-to-market prioritization. SAM analysis reveals which clinical indications, geographies, and institution types to target first. Companies that try to address the full TAM on launch typically spread sales resources too thin to achieve meaningful penetration in any segment.

Pricing strategy. ASP (average selling price) is a direct input to the market size calculation. The right price point is constrained by competitive benchmarks, value analysis committee thresholds, and reimbursement economics. Getting the pricing right before launch requires understanding the SAM.

Investor and partnership conversations. Strategic acquirers and medtech-focused venture investors scrutinize market size methodology. A market sizing analysis that uses the same source data and methodology as similar-stage deals in the same therapeutic area is more credible than a self-calculated "$X billion" figure with no transparent methodology.

Resource planning. Realistic SOM projections drive headcount planning, manufacturing capacity, and capital planning. A SOM that assumes 30% market share in year three is a resource plan that will either underdeliver or create a funding gap.

TAM: The Full Theoretical Market

TAM answers the question: if every patient or procedure that could benefit from this device were to use it, what would the annual revenue be?

The formula is straightforward:

TAM = (Number of addressable patients or procedures per year) x (Average selling price per device or per procedure)

The difficulty is in the inputs.

Calculating the patient or procedure volume. For a surgical device, the relevant measure is the number of relevant procedures performed annually. For a diagnostic device, it may be the number of tests or screenings. For an implant, it may be the incidence (new cases per year) or, for a chronic condition, the treated prevalence of the relevant condition.

Procedure volume data is available from several sources. The CDC's National Center for Health Statistics (https://www.cdc.gov/nchs/index.htm) publishes hospital discharge data and ambulatory surgery data. The Agency for Healthcare Research and Quality (AHRQ) maintains the Healthcare Cost and Utilization Project (HCUP, https://www.hcup-us.ahrq.gov/), which provides hospital inpatient and outpatient procedure data by diagnosis and procedure code. The Centers for Medicare and Medicaid Services (CMS) publishes Medicare claims data (https://www.cms.gov/data-research/statistics-trends-and-reports/medicare-fee-service-provider-utilization-payment-data) that covers procedure volumes across CPT and ICD codes for the Medicare population, which must be extrapolated to the full population with appropriate adjustment for age distribution.

Disease incidence and prevalence data is available from the CDC (https://www.cdc.gov/chronicdisease/data/index.htm), the National Institutes of Health (https://www.nih.gov/), specialty society registries, and published epidemiological studies. For rare diseases, orphan disease registries maintained by patient advocacy organizations are often the most accurate source.

Selecting the average selling price. ASP for TAM purposes should reflect the price a device would realistically be sold for in the target market, not the maximum conceivable price. Market research on competitive device ASPs, analysis of comparable cleared devices, and conversations with hospital supply chain personnel are the inputs. If the device is a consumable used multiple times per procedure, the per-procedure revenue calculation must account for that usage pattern.

TAM is a ceiling, not a target. Even companies with dominant market position rarely capture more than 30 to 50% of their SAM (which is already a fraction of TAM). TAM is a sizing tool and an investor communication signal, not a revenue plan.

SAM: The Market You Can Actually Reach

SAM narrows TAM to the patients, procedures, and geographies that your device, with its specific regulatory clearance and commercial infrastructure, can actually address.

Regulatory clearance boundary. Your device's cleared intended use under the 510(k) or approved indications under a PMA defines the patient population you can legally market to. A device cleared for use in laparoscopic cholecystectomy cannot be marketed for open abdominal procedures unless those are included in the cleared intended use. SAM is bounded by the cleared indication.

Geographic boundary. A device cleared in the United States under 510(k) has no legal authorization to be sold in the European Union, Japan, or other markets without separate marketing authorization (CE marking under the EU Medical Device Regulation (MDR, Regulation (EU) 2017/745), for example, or PMDA approval in Japan). SAM for a US-only commercial launch covers only the US addressable market.

Institution type and care setting. Some devices are appropriate only for academic medical centers or high-volume specialty centers. Some are designed for community hospital ORs or outpatient surgery centers. The institution-type filter narrows SAM to the settings where the device is realistically deployable given its complexity, required support infrastructure, and target procedure volume.

Reimbursement coverage. A device that is not reimbursed under existing CPT codes or covered by payers under existing coverage policies faces an adoption barrier that effectively narrows SAM. If reimbursement is not in place at launch, the SAM calculation should reflect that barrier rather than assume full reimbursement coverage.

The formula:

SAM = TAM x (Cleared indication / Full condition population) x (Geographic reach) x (Reimbursement coverage fraction) x (Addressable institution penetration)

Each of these multipliers is below 1. A realistic SAM for an early-stage device with a narrow cleared indication and US-only commercial launch is typically a fraction of the TAM.

SOM: What You Can Realistically Capture

SOM is the portion of SAM you expect to capture in a defined time period (typically three to five years), given your sales force capacity, competitive dynamics, clinical adoption barriers, and capital plan.

Adoption rate and ramp. Medtech adoption follows a longer adoption curve than most other commercial markets. Clinicians change procedural habits slowly, especially for devices that require technique modification or training. The average time from first clinical use to broad institutional adoption for a procedure-modifying device can be two to four years. SOM projections that assume faster ramps than analogous device launches are a common investor concern.

Sales force capacity. Each sales representative in surgical or procedural devices can realistically support a limited number of accounts, depending on the device complexity, the required proctoring time, and the geographic territory. SOM is constrained by how many representatives you can hire, train, and deploy within the planning period.

Competitive displacement. If incumbent competitors have strong clinical relationships, purchasing contracts, and established reimbursement, the rate of competitive displacement is slower than a greenfield market. SOM projections should reflect the competitive starting position, not a theoretical adoption rate unconstrained by market structure.

A practical calibration method. Find comparable device launches in the same or adjacent therapeutic areas. What market share did analogous companies achieve at three, five, and seven years post-launch? Using analogous launch data as a calibration baseline is more defensible to investors than a free-standing adoption assumption.

Top-Down vs. Bottom-Up Market Sizing

Two general methods exist for building a market sizing analysis. Each has strengths and limitations. The most credible analyses use both and check that they produce consistent results.

Top-down. Starts with a large published market figure (a market research report, an industry association estimate, or an epidemiological total) and applies a series of filters to arrive at the relevant segment. For example: "The global cardiovascular device market is $X billion annually. The atrial fibrillation ablation segment represents Y% of that market. Our cleared indication covers Z% of the AF ablation segment." The strength of top-down analysis is that it anchors to verifiable published numbers. The weakness is that the filtering steps often rely on assumptions that are not verifiable and that can compound error.

Bottom-up. Starts from first principles: number of target procedures per year (from claims data or epidemiology), fraction performed in reachable institution types, times device ASP. The strength of bottom-up is that each input is independently verifiable. The weakness is that it requires procedure-level data that may not be publicly available for every device category.

The most defensible market sizing for a medtech investor or strategic partner presentation shows both methods, acknowledges the key assumptions in each, and demonstrates that they produce consistent results within a reasonable range.

Common Market Sizing Mistakes in Medtech

Using a top-line market research figure as TAM. Citing a "$25 billion orthopedic market" or a "$10 billion wound care market" as the TAM for a specific device implies that every dollar of that market is addressable by the device. It is not. The TAM should be built bottom-up from the specific procedures or patients the device addresses.

Ignoring reimbursement constraints in SAM. A device that requires a new reimbursement code or a coverage determination before adoption can scale has a significantly narrower near-term SAM than its procedure volume would suggest.

Using best-case adoption analogues. SOM projections built on the fastest comparable market penetrations (rather than median or typical penetrations) overstate realistic outcomes.

Omitting the regulatory clearance boundary. TAM and SAM calculations that ignore the cleared indication overstate the market by including patients or procedures the device cannot legally be marketed to address.

Failing to account for competitive erosion. In categories with established competitors, SOM projections that do not include competitive response (price reductions, new product launches, preferential purchasing contracts) are typically too optimistic in years two through five.

Market Sizing as a Commercial Strategy Tool

Beyond investor communication, the market sizing analysis is a commercial strategy tool. SAM segmentation reveals which institution types, geographies, and clinical indications offer the fastest path to early adoption. SOM modeling by segment identifies the highest-priority commercial targets.

This is where market sizing connects directly to marketing and commercial execution. Buzzbox Media works with medical device companies to translate market sizing analysis into targeted go-to-market strategy: which surgeons to approach first, which institution types to prioritize, how to sequence geographic expansion, and how to structure the clinical evidence program to support the most important commercial claims.

If you are working through your medtech market sizing and want to talk through how it connects to your launch and marketing program, a 30-minute call is a good starting point. Book at https://www.buzzboxmedia.com/book.